Oral acetylcysteine as an adjunct to saline hydration for the prevention of contrast-induced nephropathy following coronary angiography: A randomized controlled trial and review of the current literature

European Heart Journal

Volumn 25, Issue 3, 2004, Pages 212-218

  Goldenberg, Ilan ^a   Shechter, Michael ^b   Matetzky, Shlomi ^a   Jonas, Michael ^a   Adam, Miriam ^a   Pres, Hanna ^a   Elian, Dan ^a   Agranat, Oren ^a   Schwammenthal, Ehud ^b   Guetta, Victor ^a,b  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Acetylcysteine; Contrast nephropathy; Coronary angiography; Renal insufficiency

Indexed keywords

ACETYLCYSTEINE; ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CONTRAST MEDIUM; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; IOPAMIDOL; NITRATE; SODIUM CHLORIDE;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CHRONIC KIDNEY FAILURE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG COST; FEMALE; HUMAN; KIDNEY DISEASE; LABORATORY TEST; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; REHYDRATION; SIDE EFFECT;

ACETYLCYSTEINE; ADMINISTRATION, ORAL; AGED; CONTRAST MEDIA; CORONARY ANGIOGRAPHY; DOUBLE-BLIND METHOD; FEMALE; FREE RADICAL SCAVENGERS; HUMANS; KIDNEY FAILURE, ACUTE; MALE; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS; SODIUM CHLORIDE;

EID: 10744230466     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ehj.2003.11.011     Document Type: Article

References (25)

1. Hou SH, Bushinsky DA, Wish JB et al. Hospital-acquired renal insufficiency: a prospective study. Am J Med 1983;74:243-8.
2. Barrett BJ, Parfrey PS. Prevention of nephrotoxicity induced by radiocontrast Agents. N Engl J Med 1994;331:1449-50.
3. Rich MW, Crecelius CA. Incidence, risk factors and clinical course of acute renal insufficiency after cardiac catheterization in patients 70 years of age or older: a prospective study. Arch Intern Med 1990;150:1237-42.
4. Brezis M, Epstein F.H. A closer Look at radiocontrast-induced nephropathy. N Engl J Med 1989;320:179-81.
5. Weisberg LS, Kurnik PB, Kurnik BRC. Risk of radiocontrast nephropathy in patients with and without diabetes mellitus. Kidney Int 1994;45:259-65.
6. Parfrey PS, Griffiths S.M, Barrett BJ et al. Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both: a prospective controlled study. N Engl J Med 1989;320:143-9.
7. Barrett BJ. Contrast nephrotoxicity. J Am Soc Nephrol 1994;5:125-37.
8. Tepel M, van Der Giet M, Schwarzfeld C et al. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000;343:180-4.
9. Rihal CS, Textor SC, Grill DE et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002;105:2259-64.
10. Diaz-Sandoval LJ, Kosowsky BD, Losordo DW. Acetylcysteine to prevent angiography-related renal tissue injury (the APART trial). Am J Cardiol 2002;89:356-8.
11. Briguori C, Manganelli F, Scarpato P et al. Acetylcysteine and contrast agent-associated nephrotoxicity. J Am Coll Cardiol 2002;40:298-303.
12. Shyu KJ, Cheng JJ, Kuan P. Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure. J Am Coll Cardiol 2002;40:1383-8.
13. Durham JD, Caputo C, Dokko J et al. A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography. Kidney Int 2002;62:2202-7.
14. Allaqaband S, Tumuluri R, Malik AM et al. Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy. Catheter Cardiovasc Interv 2002;57:279-83.
15. Boccalandro F, Amhad M, Smalling RW et al. Oral acetylcysteine does not protect renal function from moderate to high doses of intravenous radiographic contrast. Catheter Cardiovasc Interv 2003;58:336-41.
16. Kay J, Chow WH, Chan TM et al. Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial. JAMA 2003;289:553-8.
17. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
18. Grossman E, Messerli FH, Goldbourt U. Antihypertensive therapy and the risk of malignancies. Eur Heart J 2001;22:1343-52.
19. Weisberg LS, Kurnik PB, Kurnik BR. Radiocontrast-induced nephropathy in humans: Role of renal vasoconstriction. Kidney Int 1992;41:1408-15.
20. Safirstein R, Andrade L, Vieira JM. Acetylcysteine and nephrotoxic effects of radiographic contrast agents: a new use for an old drug. N Engl J Med 2000;343:210-1.
21. Brogstrom L, Kagedal B, Paulsen O. Pharmacokinetics of N-acetylcysteine in man. Eur J Clin Pharmacol 1986;31:217-22.
22. Solomon R, Werner C, Mann D et al. Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents. N Engl J Med 1994;331:1416-20.
23. Mueller C, Buerkle G, Buettner HG et al. Prevention of contrast media-associated nephropathy. Arch Intern Med 2002;162:329-36.
24. Eisenberg RL, Bank WO, Hedgock MW. Renal failure after major angiography can be avoided with hydration. Am J Roentgenol 1981;136:859-61.
25. Taylor AJ, Hotchkiss D, Morse RW et al. PREPARED: preparation for angiography in renal dysfunction: a randomized trial of inpatient versus outpatient hydration protocols for cardiac catheterization in mild to moderate renal dysfunction. Chest 1998;114:1570-4.